神经调节器控制多巴胺基神经元中的能量储备
Camila Pulido1,2, Matthew S Gentry3, Timothy A Ryan1,2
1Department of Biochemistry & Biophysics, Weill Cornell Medicine, New York, NY.
bioRxiv : the preprint server for biology
|September 2, 2025
概括
多巴胺信号中脑神经元储存糖原, 提供对代谢压力的弹性. 这种信号或糖原获取的丧失增加了脆弱性,可能导致帕金森病的神经退行.
科学领域:
- 神经科学
- 细胞代谢
- 神经退行性疾病
背景情况:
- 大脑,尤其是中脑的多巴胺神经元,
- 这些神经元与帕金森病 (PD) 有关,可疑与生物能量缺陷有关.
- 尽管存在相关酶,但糖原作为神经元中的能量储存器的作用仍然不清楚.
研究的目的:
- 研究中脑多巴胺能神经元中的糖原可用性的调节.
- 确定多巴胺信号在神经元能量平衡中的作用.
- 探索神经保护和帕金森病发病的含义.
主要方法:
- 主要的中脑多巴胺基神经元培养.
- 对多巴胺自身受体 (D2R) 信号通路的研究.
- 在低代谢条件下评估神经元功能.
主要成果:
- 多巴胺通过D2R信号在多巴胺神经元中储存糖原.
- 在代谢压力期间,糖原储存的存在使神经元功能具有显著的弹性.
- 失去多巴胺信号或降低糖原的获取使神经元对燃料缺乏过敏.
结论:
- 神经元利用细胞外信号,如多巴胺,调节局部能量代谢.
- 糖原作为中脑多巴胺神经元的重要燃料储备.
- 在帕金森病中,受损的多巴胺信号传递和随后的糖原储量损失可能会增加对神经退行症的敏感性.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Neurochemical Transmission: Sites of Drug Action
2.6K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.6K
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Adrenergic Neurons: Neurotransmission
4.1K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
4.1K
Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K


